All In Biotech

Free tool

FAERS Monitor: Brekiya (Autoinjector)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215400 or its brand name (Brekiya (Autoinjector), Dihydroergotamine Mesylate). Reports on generic versions are filed under their own applications.

Reports

840

Serious

653

78% of reports

Hospitalization

140

Death reported

21

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective387
  • off label use359
  • hyperhidrosis356
  • nausea341
  • nightmare339
  • sedation339
  • product use in unapproved indication293
  • nephrolithiasis252
  • migraine79
  • treatment failure57
  • dyspnoea52
  • abdominal pain48
  • diarrhoea48
  • cough46
  • weight decreased43

Reports by year received

View as table
YearReports
200417
200516
200624
200724
200820
200915
201018
201126
201226
20132
20142
20152
20169
201718
201814
201926
202018
202164
202270
202350
2024125
202584
2026170

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,319 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sedationSignal339328.3302.2109,013
nightmareSignal339247.7228.082,383
nephrolithiasisSignal252138.3124.734,105
hyperhidrosisSignal35669.464.124,009
product use in unapproved indicationSignal29329.627.08,165
migraineSignal7920.716.81,470
treatment failureSignal5717.213.4859
nauseaSignal34110.89.93,137
off label useSignal35910.39.53,123
drug ineffectiveSignal3877.46.82,259
abdominal painSignal485.23.9159
coughSignal464.13.1106
weight decreasedSignal433.92.989
dyspnoeaSignal522.31.838
diarrhoea481.91.419

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.